Simplexia

The project develops a vaccine against genital herpes. Genital herpes is the most widespread sexually transmitted disease in the world with 20-30% of the population infected. The annual market is estimated to be SEK 2.8B annually only in US. The project has a competitive advantage since it can protect people even if they are infected with the virus causing oral herpes.